cp-945598 and Fatty-Liver

cp-945598 has been researched along with Fatty-Liver* in 1 studies

Other Studies

1 other study(ies) available for cp-945598 and Fatty-Liver

Article	Year
Blocking Alcoholic Steatosis in Mice with a Peripherally Restricted Purine Antagonist of the Type 1 Cannabinoid Receptor. Journal of medicinal chemistry, 2018, 05-24, Volume: 61, Issue:10 Type 1 cannabinoid receptor (CB1) antagonists have demonstrated promise for the treatment of obesity, liver disease, metabolic syndrome, and dyslipidemias. However, the inhibition of CB1 receptors in the central nervous system can produce adverse effects, including depression, anxiety, and suicidal ideation. Efforts are now underway to produce peripherally restricted CB1 antagonists to circumvent CNS-associated undesirable effects. In this study, a series of analogues were explored in which the 4-aminopiperidine group of compound 2 was replaced with aryl- and heteroaryl-substituted piperazine groups both with and without a spacer. This resulted in mildly basic, potent antagonists of human CB1 (hCB1). The 2-chlorobenzyl piperazine, 25, was found to be potent ( K Topics: Alcohols; Animals; Cannabinoid Receptor Antagonists; Fatty Liver; Female; Humans; Mice; Mice, Inbred C57BL; Models, Molecular; Molecular Structure; Protein Conformation; Receptor, Cannabinoid, CB1; Structure-Activity Relationship; Tissue Distribution	2018

Article

Year

Blocking Alcoholic Steatosis in Mice with a Peripherally Restricted Purine Antagonist of the Type 1 Cannabinoid Receptor.

Journal of medicinal chemistry, 2018, 05-24, Volume: 61, Issue:10

Type 1 cannabinoid receptor (CB1) antagonists have demonstrated promise for the treatment of obesity, liver disease, metabolic syndrome, and dyslipidemias. However, the inhibition of CB1 receptors in the central nervous system can produce adverse effects, including depression, anxiety, and suicidal ideation. Efforts are now underway to produce peripherally restricted CB1 antagonists to circumvent CNS-associated undesirable effects. In this study, a series of analogues were explored in which the 4-aminopiperidine group of compound 2 was replaced with aryl- and heteroaryl-substituted piperazine groups both with and without a spacer. This resulted in mildly basic, potent antagonists of human CB1 (hCB1). The 2-chlorobenzyl piperazine, 25, was found to be potent ( K

Topics: Alcohols; Animals; Cannabinoid Receptor Antagonists; Fatty Liver; Female; Humans; Mice; Mice, Inbred C57BL; Models, Molecular; Molecular Structure; Protein Conformation; Receptor, Cannabinoid, CB1; Structure-Activity Relationship; Tissue Distribution

2018